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Background: Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). 
Cinacalcet use is controversial in non-dialysis patients.
Methods: This retrospective observational study recruited patients receiving cinacalcet (off-label use) in 2010 and 
2011. Patients were followed for three years from the beginning of treatment using an intention-to-treat approach.
Results: Forty-one patients were studied: 14 CKD stage 3 (34.1%), 21 CKD stage 4 (51.2%), and 6 CKD stage 5 
(14.6%).  Median baseline parathyroid hormone (PTH) was 396 (101-1,300) pg/mL. Upon cinacalcet treatment (22 ± 
12 months), PTH levels decreased by ≥ 30% in 73.2% of patients (P < 0.001; 95% confidence interval [CI], 59-87%), 
with a mean time for response of 18.7 months (95% CI, 15.4-22.1). Sixteen patients were followed for 36 months 
and treated for 32 ± 9 months. Mean reduction in their PTH levels was 50.1% (P < 0.001; 95% CI, 33.8-66.4%) at 
36 months, with 62.5% of patients (P < 0.001; 95% CI, 35.9-89.1%) presenting reductions of ≥ 30%. Serum calcium 
levels decreased from 9.95 ± 0.62 mg/dL to 9.21 ± 0.83 and 9.12 ± 0.78 mg/dL at 12 and 36 months, respectively (P 
< 0.001). Serum phosphorus levels increased from 3.59 ± 0.43 to 3.82 ± 0.84 at 12 months (P = 0.180), remaining 
so at 36 months (P = 0.324). At 12 and 36 months, 2 (12.5%) patients experienced hypocalcemia. Meanwhile, 1 
(6.3%) and 4 (25.0%) patients reported hyperphosphatemia at 12 and 36 months, respectively.
Conclusion: Cinacalcet remained effective for at least 36 months in non-dialysis patients with SHPT. Electrolytic 
disturbances were managed with concurrent use of vitamin D and its analogs or phosphate binders.
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Introduction
Secondary hyperparathyroidism (SHPT) is a frequent 
complication in patients with chronic kidney disease 
(CKD) that appears in the early stages of the disease and 
is exacerbated by worsening kidney function [1]. Sus-
tained overproduction of parathyroid hormone (PTH) 
induces a systemic disorder characterized by high bone 
turnover and vascular calcification, which increase the 
risk of bone fracture and cardiovascular mortality [2,3].
Treatment of SHPT aims to decrease PTH levels while 
maintaining calcium and phosphorus serum levels 
within normal ranges [4]. Cinacalcet (Amgen, Thousand 
Oaks, CA, USA), as well as vitamin D and its analogs, 
phosphate binders, parathyroidectomy, and a restricted 
dietary intake of phosphorus, can be used to slow the 
progression of SHPT [1-4]. Cinacalcet is a type II cal-
cimimetic that decreases PTH synthesis and release by 
increasing the sensitivity of calcium-sensing receptors in 
the parathyroid chief cells to extracellular calcium [4]. 
Cinacalcet is currently indicated for the treatment of 
SHPT in patients with end-stage renal disease undergo-
ing dialysis [5]. It has been shown to remain effective for 
at least 3.5 years of treatment [6,7]. 
The treatment of SHPT with cinacalcet has also been 
evaluated in non-dialysis patients [8-16]. In a phase III 
clinical trial, cinacalcet decreased PTH levels by 43%. 
However, it also caused hypocalcemia in 62% of patients, 
although they were mostly asymptomatic. More worry-
ingly, it increased phosphorus serum levels by 21.4% [8]. 
Similar or greater reductions in PTH levels were also ob-
served in other clinical practice studies [10-16]. 
SHPT is a chronic and progressive condition that 
worsens over time, even in non-dialysis patients. Conse-
quently, prolonged treatment is required. However, the 
effectiveness of cinacalcet has only been evaluated in 
the short term. The long-term effectiveness and safety 
of cinacalcet in non-dialysis patients have not yet been 
studied.
Therefore, our aim in this study was to evaluate the 
long-term effectiveness and safety of cinacalcet in pa-
tients with CKD and SHPT who had not received renal 
replacement therapy (RRT) or renal transplantation (RT).
Methods
Materials and methods
An analytical, retrospective, observational, non-place-
bo-controlled and multi-center lead-in study was con-
ducted and previously reported elsewhere [10,11]. The 
lead-in study followed patients for up to 12 months. The 
same patients were then followed for up to 36 months in 
this extension study.
The inclusion criteria were adults diagnosed with CKD 
and SHPT who had not received RRT or RT and had 
taken cinacalcet, under off-label use, from the Outpa-
tient Pharmacy Service (OPS) during 2010 and 2011 and 
then continued cinacalcet treatment for up to 36 months 
before beginning RRT (hemodialysis or peritoneal dialy-
sis) or RT. SHPT was diagnosed if PTH serum levels were 
sustained for 6 months above 200 pg/mL with Ca serum 
levels above 9 mg/dL. The exclusion criterion was partic-
ipation in an active cinacalcet clinical trial. The cinacal-
cet prescription criteria were patients with elevated PTH 
levels or those presenting a sharp increase in PTH levels. 
Individualized dosage adjustments were made as needed 
based on each patient’s biochemical values. Patients first 
received standard treatment if their serum calcium levels 
allowed it [10,11]. The Clinical Research Ethics Commit-
tees of the Vall d’Hebron University Hospital and Bell-
vitge University Hospital approved this study (approval 
no. CEIC VH-3772). Neither written nor verbal consent 
for study participation was systematically obtained. The 
study was non-interventional and retrospective, using 
routine data collected from clinical records. Moreover, 
most of the patients were outpatients, which made them 
difficult to find and contact. Verbal consent was obtained 
when feasible from patients who made routine visits to 
the hospital outpatient setting during the study period. 
The Ethics Committee approved this procedure, which is 
routine for observational retrospective studies. To protect 
patient privacy, anonymized data are available on re-
quest from the corresponding author.
The patients were followed for up to 36 months from 
the beginning of cinacalcet treatment using medical data 
collected every 3 months. As in the lead-in study, the 
compiled information contained biodemographic data; 
therapeutic details about the use of cinacalcet, vitamin D 
and its analogs, phosphate binders, and calcium supple-
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ments; and biochemical values for PTH, serum calcium 
and phosphorus, albumin, 25-OH-vitamin D, serum and 
urine creatinine, proteinuria, alkaline phosphatase, and 
gamma-glutamyl-transferase [10,11]. Serum PTH levels 
were measured by Liaison XL (DiaSorin, Stillwater, USA) 
and Immulite 2000 XPi (Siemens Healthcare, Erlangen, 
Germany) at Vall d’Hebron University Hospital and Bell-
vitge University Hospital. The cinacalcet dose was report-
ed as the average weekly dosage.
The long-term effectiveness of cinacalcet was measured 
by analyzing changes during the follow-up period in the 
number of patients with reductions in their PTH levels 
of 30% or more from their baseline values. Secondary 
effectiveness outcomes included changes in mean PTH 
levels from baseline to 36 months. Long-term safety was 
assessed by measuring changes in the mean serum levels 
of calcium and phosphorus and incidences of hypocal-
cemia (two consecutive calcium readings of < 8.4 mg/
dL) and hyperphosphatemia (phosphorus > 4.5 mg/dL) 
[3] from baseline to 36 months. The reasons for stopping 
cinacalcet treatment were also recorded.
Either the Cockcroft and Gault [17] or the Modification 
of Diet in Renal Disease [18] study equation was used to 
stratify patients by their estimated glomerular filtration 
rate (eGFR): CKD stage 3, 30-59 mL/min/1.73 m2; CKD 
stage 4, 15-29 mL/min/1.73 m2; and CKD stage 5, < 15 
mL/min/1.73 m2. 
Statistical analysis
The principal analysis was conducted using the inten-
tion-to-treat approach. To evaluate the effectiveness of 
the primary and secondary variables, the student-Fisher 
t test was used for continuous variables with a normal 
distribution, and a variance test such as two-way ANOVA 
was used for repeated measures. The Friedman or Krus-
kal-Wallis test was used to compare variables that did 
not follow a normal distribution. Fisher’s exact test was 
applied for categorical variables. Because 36 months of 
follow-up were not achieved for every study participant, 
a survival analysis was also performed. Confidence in-
tervals (CIs) were calculated using a Student t-paired test 
with α = 0.05. The number of patients was not predefined 
because all the patients with available records from our 
OPS in 2010 and 2011 were considered for the study. 
In the safety analysis, all patients were included be-
Table 1. Baseline characteristics of the patients 
Characteristic
Cinacalcet lead-in 





   Male 20 (48.8) 11 (68.7)
   Female 21 (51.2) 5 (31.3)
Age (yr) 66.02 ± 15.14 62.00 ± 17.27
CKD stage
   CKD 3 14 (34.1) 5 (31.3)
   CKD 4 21 (51.3) 9 (56.2)
   CKD 5 6 (14.6) 2 (12.5)
Cinacalcet dose (mg/wk) 174.15 ± 82.49 157.5 ± 65.3
Concomitant treatment
   Vitamin D and analogs 22 (53.7) 7 (43.8)
      Calcitriol 15 (36.6) 6 (37.5)
      Paricalcitol 6 (14.6) 1 (6.3)
      Calcifediol 1 (2.4) 0 (0)
   Phosphate binders 6 (14.6) 3 (18.8)
      Calcium containing 4 (9.8) 3 (18.8)
      Sevelamer 1 (2.4) 0 (0)
      Lanthanum carbonate 1 (2.4) 0 (0)
   Calcium supplement 1 (2.4) 0 (0)
Concomitant comorbidities
   Hypertension 38 (92.7) 13 (81.3)
   Dyslipidemia 29 (70.7) 7 (43.8)
   Other cardiovascular disease 28 (68.3) 10 (62.5)
   Renal and urologic disease 22 (53.7) 11 (68.8)
   Diabetes 13 (31.7) 5 (31.3)
   Hyperuricemia 13 (31.7) 4 (25.0)
   Obesity 11 (26.8) 3 (18.8)
   Active smoker 8 (19.5) 4 (25.0)
   Active neoplasm 4 (9.8) 1  (6.3)
   Endocrine disease 3 (7.3) 1 (6.3)
   Osteoporosis 2 (4.9) 4 (25.0)
Biochemical values
   Parathyroid hormone (pg/mL) 396 (101-1,300) 354 (197-837)
   Serum creatinine (mg/dL) 2.93 ± 1.12 2.86 ± 0.93
   Glomerular filtration rate 24.26 ± 10.90 24.93 ± 9.43
   Albumin (mg/dL) 4.19 ± 0.26 4.23 ± 0.33
   Serum calcium (mg/dL) 9.76 ± 0.71 9.95 ± 0.62
   Serum phosphorus (mg/dL) 3.83 ± 0.70 3.59 ± 0.43
   C alcium phosphate product 
(mg2/dL2)
37.32 ± 6.72 35.44 ± 4.03
Data are presented as number (%), mean ± standard deviation, or median 
(interquartile range).
CKD, chronic kidney disease.
aReference: Pérez et al (Circ Farm 2015;7:5-12) [11].
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cause all of them had received at least one dose of cina-
calcet. Adverse events were tabulated by their incidence 
and severity. Adverse reactions were presumed to be 
related to cinacalcet treatment. Calcium and phosphorus 
serum levels were evaluated in a way similar to that used 
for the efficacy variables. Statistical analyses were con-
ducted using SPSS ver. 15.0 software (SPSS Inc., Chicago, 
USA).
Results
A total of 41 patients were evaluated in the lead-in 
study, and their baseline characteristics are summarized 
in Table 1. The patients were followed up for a mean pe-
riod of 26 ± 9 months and were treated with cinacalcet for 
a mean period of 22 ± 12 months. Sixteen of them were 
followed for 36 months, and those patients received cina-
calcet for a mean period of 32 ± 9 months. Their demo-
graphic and analytic characteristics are shown in Table 
1 and 2. Twenty-five patients had a shorter follow-up 
period because the study had closed (48.0%) or because 
they initiated RRT (44.0%), were lost to follow-up (4.0%), 
or died (4.0%). However, 68% of patients were still on 
cinacalcet treatment on their last recorded visit. 
At the end of the study, the mean cinacalcet dose was 
204.38 ± 154.62 mg/week (29 mg/day). The most com-
mon daily doses of cinacalcet were < 30 mg/day (42.9%) 
and 30 to 60 mg/day (28.6%), followed by 30 mg/day 
(14.3%), 60 mg/day (7.1%), and > 60 mg/day (7.1%). For 
patients receiving < 30 mg/day, the most common dose 
was 30 mg of cinacalcet three times a week (14.5%), fol-
lowed by 30 mg five times a week (7.1%), 30 mg six times 
a week (7.1%), 30 mg weekly (7.1%), and other combina-
tions (7.1%). At the end of the study, common daily doses 
of cinacalcet were ≤ 30 mg/day in the 60.0% and 55.5% of 
patients who started with CKD 3 and CKD 4, respectively. 
Patient who started with CKD 5 and ended the study with 
cinacalcet treatment used 60 mg/day. At baseline, 43.8% 
and 18.8% of patients used vitamin D and its analogs 
and phosphate binders, respectively, increasing to 62.5% 
and 18.8% of patients at 12 months and 87.5% and 25.0% 
of patients at the end of the study. None of the patients 
used calcium supplements. At the end of the study, the 
vitamin D and its analogs used were calcitriol (37.5%), 
calcifediol (25.0%), paricalcitol (25.0%), and alfacalcidol 
Table 2. Changes in biochemical values over the 36-month treatment period with cinacalcet (n = 16) 
Biochemical value  
(n = 16)
Baseline Month 3 Month 12 Month 24 Month 36
PTH (pg/mL) 401.9 ± 170.6 292.78 ± 161.22 222.66 ± 131.66 184.12 ± 196.87 198.92 ± 154.07
sCr (mg/dL) 2.9 ± 0.9 2.90 ± 0.77 2.74 ± 1.04 2.96 ± 0.96 3.12 ± 1.04
GFR 24.9 ± 9.4 24.53 ± 9.68 37.05 ± 52 19.32 ± 5.32 21.61 ± 10.48
Alb (mg/dL) 4.2 ± 0.3 4.02 ± 0.28 4.19 ± 0.40 4.12 ± 0.35 4.09 ± 0.40
sCa (mg/dL) 9.95 ± 0.62 9.46 ± 0.72 9.21 ± 0.83 9.32 ± 0.82 9.12 ± 0.78
sP (mg/dL) 3.59 ± 0.43 3.73 ± 0.58 3.82 ± 0.84 3.84 ± 0.69 3.78 ± 0.85
CaxP (mg2/dL2) 35.44 ± 4.03 35.18 ± 5.74 35.31 ± 9.33 35.63 ± 6.75 34.09 ± 6.48
25-OHD (ng/mL) - - 17.17 ± 8.25 18.81 ± 11.68 19.54 ± 10.98
Data are presented as mean ± standard deviation.
Conversion factor for units: PTH in pg/mL to pmol/L, × 0.11; sCr in mg/dL to μmol/L, × 88.4; GFR in mL/min/1.73 m2 to mL/sec/1.73 m2, × 0.017; Alb in mg/dL to g/L, 
× 10; sCa in mg/dL to mmol/L, × 0.25; sP in mg/dL to mmol/L, × 0.32; 25-OHD in ng/ml to pmol/L, × 2,400.
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Figure 1. Survival therapy success, measured as achieving a 
reduction of ≥ 30% in the parathyroid hormone level (n = 41).
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(6%), and some of the phosphate binders used contained 
calcium (25.0%). 
The survival analysis showed that 73.2% (P < 0.001; 95% 
CI, 59-87%) of patients achieved at least a 30% reduction 
in their PTH levels during the follow-up period. The mean 
time for response to treatment (PTH reduction > 30%) was 
18.7 months (95% CI, 15.4-22.1 months) (Fig. 1). 
For patients followed for 36 months, the mean reduc-
tion in PTH levels was 50.1% (P < 0.01; 95% CI, 33.8-
66.4%), with 62.5% of patients (P < 0.001; 95% CI, 35.9-
89.1%) presenting at least a 30% reduction in their PTH 
levels (Table 3). Cinacalcet significantly reduced PTH 
levels in the first year of treatment and then maintained 
that reduction for up to 36 months. A marked decrease 
Table 3. Effectiveness outcomes during 36 months of cinacalcet therapy: overall population (n = 16)
Follow up
Proportion of patients with a reduction of  
≥ 30% in their PTH levels
Mean PTH reduction
Month 3 31.3% 23.5%
P = 0.05 (95% CI, 5.7-56.8) P = 0.02 (95% CI, 1.3-36.4)
Month 12 50.0% 38.9%
P < 0.001 (95% CI, 22.5-77.5) P = 0.004 (95% CI, 27.2-57.5)
Month 36 62.5% 50.1%
P < 0.001 (95% CI, 35.9-89.1) P < 0.001 (95% CI, 33.8-66.4)
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Figure 2. Changes in parathyroid hormone (PTH) levels over 
36 months of cinacalcet treatment (n = 16; mean, 95% confi-
dence interval [CI]).
Table 4. Effectiveness outcomes during 36 months of cinacal-
cet therapy: results according CKD stages (n = 16)
Outcome CKD3 CKD4 CKD5 P value
P roportion of patients with a reduc-
tion of ≥ 30% in their PTH levels
60.0% 66.7% 50.0% 0.90
Mean PTH reduction -44.4% -54.1% -48.4% 0.86
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Figure 4. Changes in phosphorus (P) levels over 36 months of 
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Figure 3. Changes in calcium (Ca) levels over 36 months of 
cinacalcet treatment (n = 16; mean, 95% confidence interval 
[CI]).
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was observed after just three months of cinacalcet treat-
ment. Changes in PTH levels over the 36 months of treat-
ment are shown in Fig. 2. No significant differences were 
observed in the effectiveness of cinacalcet among the 
groups with different stages of CKD (Table 4).
Cinacalcet reduced calcium levels and increased phos-
phorus levels, as can be seen in Fig. 3 and 4, respectively. 
At baseline, the mean calcium level was 9.95 ± 0.62 mg/
dL, which was reduced by 7.4% at 12 months (P < 0.001) 
and 8.3% at 36 months (P < 0.001). At baseline, the mean 
phosphorus level was 3.59 ± 0.43 mg/dL, which in-
creased, without statistical significance, by 6.3 and 5.7% 
at both 12 months (P = 0.180) and 36 months (P = 0.324).  
Cinacalcet treatment induced hypocalcemia and hy-
perphosphatemia. No patients presented hypocalcemia 
at baseline, whereas 2 (12.5%) patients did at 12 months. 
Hypocalcemia persisted for up to 36 months of cinacalcet 
treatment. Corrective measures consisted of decreasing 
or stopping cinacalcet treatment and/or increasing the 
uptake of vitamin D and its analogs. Similarly, no patients 
presented hyperphosphatemia at baseline, but 1 (6.3%) 
and 4 (25.0%) patients did at 12 months and 36 months, 
respectively. 
Cinacalcet treatment was discontinued by 25% of pa-
tients before 36 months, although 12.5% of them went 
on to restart treatment. One patient stopped twice. The 
reasons for withdrawing treatment were: hypocalcemia 
(6.3%), non-compliance (6.3%), interactions (6.3%), 
other adverse reactions (6.3%), and unknown (6.3%). 
Compared to the overall population of the lead-in study 
[10,11], treatment withdrawal occurred mainly in the first 
12 months of treatment (Table 5). One patient treated 
with cinacalcet died after admission to a hospital with a 
gastrointestinal hemorrhage whose cause could not be 
assessed. In addition, the patient showed acidosis and 
during hospitalization presented ventricular fibrillation 
with QT prolongation. Eco-Doppler showed moderate 
aortic stenosis, severe mitral insufficiency, and moder-
ate ventricular dysfunction. At the time of hospitaliza-
tion, the patient was receiving furosemide, allopurinol, 
amiodarone, calcitriol, cinacalcet, omeprazole, calcium/
vitamin D supplement, atorvastatin, and pegylated epo-
etin beta, and their featured analytical values were 3,89 
mg/dL potassium, 1.9 mg/dL magnesium, and 7.7 mg 
calcium. 
Patients in the lead-in and extension studies experi-
enced adverse events that did not stop them from con-
tinuing cinacalcet treatment: 4 patients reported gas-
trointestinal discomfort; 1 presented muscle spasms, 1 
experienced paresthesia, and 1 reported alopecia. Most 
of those adverse events occurred in the first 12 months of 
cinacalcet treatment [10,11]. 
Discussion
To the best of our knowledge, this is the first study 
to evaluate the long-term effectiveness and safety of 
cinacalcet in a reasonable sample size of non-dialysis 
patients. We not only analyzed changes in biochemical 
values for 36 months, but we also carried out a survival 
Table 5. Reasons for withdrawal of cinacalcet treatment in the lead-in and extension studies (n = 41)
Description (n = 41)
Causes of withdrawal produced 
before or at 12 mo of follow-up
Causes of withdrawal produced after 12 mo of follow-up
Follow-up period: up to 36 mo Follow-up period: less than 36 moa
Hypocalcemia 4 1 2
Gastrointestinal discomfort and other intolerances
     Gastrointestinal discomfort 2 - -
     Suffocation 1 - -
     Bone pain - - 1
     Lichenoid reaction - 1 -
Non-compliance 1 - -
Interactions 1 - -
Excessive effectiveness 1 - -
Unknown 1 1 -
Death - - 1b
aPatients that not meet inclusion criteria of extension study; bwith hypocalcemia.
Part of this data was from Pérez-Ricart et al (PLoS One 2016;11:e0161527) [10] and Pérez et al (Circ Farm 2015;7:5-12) [11].
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analysis. 
The survival curve showed that the mean time for 
achieving a reduction of ≥ 30% in the PTH level in non-
dialysis patients with SHPT was 18.7 months (95% CI, 
15.4-22.1 months). In the lead-in study [10,11], we ob-
served that 72.7% of patients with baseline PTH levels > 
300 pg/mL presented reduced PTH levels as early as in 
the first three months of cinacalcet treatment. By con-
trast, only 16.7% of patients with baseline PTH levels < 
300 pg/mL showed the same reductions in their PTH 
levels. However, 58.3% of patients with a baseline PTH 
level < 300 pg/mL displayed a reduction of ≥ 30% in their 
PTH levels after 12 months of cinacalcet treatment [10,11], 
which explains the results found in this extension study.
NICE recommends the continuation of cinacalcet treat-
ment in hemodialysis patients if the patients achieve a re-
duction of ≥ 30% in their PTH levels after four months of 
treatment [19]. Our study evaluated non-dialysis patients 
with a mean PTH concentration of 396 (101-1,300) pg/
mL in the lead-in study [10,11] and 354 (197-837) pg/mL 
in this extension study. These PTH levels are greater than 
those found in other epidemiological studies in non-
dialysis patients, which reported values of 67 to 90 pg/
mL, 90 to 160 pg/mL, and 220 to 250 pg/mL in patients 
with CKD3, CKD4, and CKD5, respectively [20-22]. In 
addition, our mean PTH level was far above the NKF Kid-
ney Disease Outcomes Quality Initiative (NKF-K/DOQI) 
recommendations [3] and even greater than the baseline 
PTH levels for CKD3 and CKD4 observed in a previous 
phase III clinical trial [8]. Moreover, PTH levels negatively 
correlate with eGFR [2,3], indicating that our patients 
would present increasing PTH levels over time. PTH lev-
els also correlate with high bone turnover [23], increasing 
the fluid loss of calcium and phosphorus [4,12,24], which 
is, in turn, associated with soft tissue calcification [25] 
and cardiovascular morbidity and mortality [2,3]. There-
fore, non-dialysis patients with high PTH levels could be 
considered high-risk patients. It would be interesting to 
debate how long clinicians should be prepared to wait 
to achieve a PTH reduction of 30% in such high-risk pa-
tients.
This study found that cinacalcet is not only effective in 
the short term [8-16], but also in the long-term in pa-
tients not yet on dialysis. In this study, 50.0% of patients 
achieved at least a 30% reduction in their PTH level, 
which increased slightly to 62.5% of patients with 36 
months of follow-up data. The overall mean reduction 
in PTH levels was 38.9%, becoming 50.1% at 36 months. 
Thus, cinacalcet was effective for at least 36 months. 
These results are consistent with those from long-term 
studies of cinacalcet in hemodialysis patients [6,7]. More-
over, we observed that cinacalcet significantly reduced 
PTH levels after three months and was equally effective 
for all stages of CKD, which agrees with the results of the 
lead-in study [10,11].
Cinacalcet maintained its effectiveness without requir-
ing a large increase in its dose. In this study, the cinacal-
cet dose increased by 29.8% from baseline to 36 months, 
but it still remained close to the recommended starting 
dose for cinacalcet in hemodialysis patients [5]. These 
findings were similar to those obtained by Sprague et al [6] 
in dialysis patients, in whom cinacalcet remained effec-
tive for at least 3.5 years without considerable increases 
in dosage. Furthermore, cinacalcet was previously re-
ported to maintain PTH levels for 24 months in 8 non-
dialysis patients [13].
The present study might have recruited a higher num-
ber of cinacalcet responders. Compared to the lead-in 
study, this study had a higher proportion of male pa-
tients, patients with diabetes mellitus, younger patients, 
and patients with lower baseline PTH levels. Some au-
thors have reported that diabetes mellitus could decrease 
PTH secretion [26], and Kim et al [27] found that non-
responders to cinacalcet tended to be younger and male. 
However, factors affecting cinacalcet response remain 
unclear. The main reasons for losing patients in this ex-
tension study were study closure and patients starting 
RRT. However, many patients continued cinacalcet after 
starting RRT. Thus, patient losses did not appear to affect 
the results of this study.
In this study, mean serum calcium levels decreased at 
the onset of cinacalcet treatment but remained stable 
from 12 to 36 months. The number of hypocalcemia cases 
also remained stable from 12 to 36 months. Cinacalcet-
related hypocalcemia has been widely reported [5]. Hy-
pocalcemia seems to be linked to the reduction in PTH 
levels, which decreases the release of calcium from bones 
[4] and increases calcium excretion from the kidneys 
[12,24]. Hypocalcemia is the most concerning adverse 
effect of cinacalcet treatment in non-dialysis patients. 
However, it can be treated by elevating the intake of vita-
min D and its analogs, which stimulates the intestinal ab-
Kidney Res Clin Pract   Vol. 38, No. 2, June 2019
236 www.krcp-ksn.org
sorption of calcium [1] and could prevent hypocalcemia. 
At 36 months, 87.5% of patients received vitamin D and 
its analogs, although the sharpest increase in the inci-
dence of hypocalcemia occurred in the first three months 
of cinacalcet treatment.
Another worrying issue is the short-term increase in 
phosphorus levels reported in non-dialysis patients on 
cinacalcet. CKD3 and CKD4 patients have residual renal 
function that could increase the tubular reabsorption 
of phosphorus due to the decreased PTH levels [12,24]. 
Elevated phosphorus levels are the primary cause of vas-
cular calcification [25]. Palmer [28] demonstrated that 
the all-cause mortality risk increased by 18% for each 
1-mg/dL increase in the phosphorus level (relative risk 
[RR], 1.29; 95% CI, 1.12-1.48) in non-dialysis patients; 
the correlation was more consistent when phosphorus 
levels were > 5.5 mg/dL [28], although other studies have 
reported similar findings for phosphorus levels > 7 mg/
dL [29].
In this study, we observed an increased number of 
hyperphosphatemia cases between 12 and 36 months. 
Unlike the lead-in study [10,11], this study did not find 
any baseline episodes of hyperphosphatemia. The loss 
of patients due to their initiation of RRT did not influ-
ence these results because hyperphosphatemia was not 
a main or routine reason to start RRT [30]. Surprisingly, 
mean phosphorus levels decreased and remained stable 
between 15 and 36 months, reversing the trend observed 
during the first 15 months of cinacalcet treatment.
Our observations suggested two types of patients. Some 
patients displayed increased phosphorus levels upon 
cinacalcet treatment in both the short- and long-term. In 
addition, these increases were favored by a high intake of 
vitamin D and its analogs, which stimulate the intestinal 
absorption of phosphorus [1]. By contrast, phosphorus 
levels in some patients were unaffected or decreased in 
response to cinacalcet, possibly because of better control 
of PTH levels. Rodriguez et al [31] showed a strong as-
sociation between PTH and phosphorus concentrations, 
and Frazão et al [32] demonstrated better control of phos-
phorus levels in dialysis patients when PTH levels were 
effectively decreased by cinacalcet or conventional treat-
ment with vitamin D and its analogs and/or phosphate 
binders [32]. Consequently, better control of PTH levels 
through cinacalcet treatment might have maintained or 
decreased the phosphorus levels in some non-dialysis 
patients in our study. Deteriorating renal function could 
also explain the decrease in phosphorus levels because 
phosphorus reabsorption requires residual renal function 
[12,24]. However, in this study, eGFR did not significantly 
decrease throughout the 36 month study period.
We noted that cinacalcet was well tolerated for at least 
36 months, with patients experiencing the most adverse 
events during the first 12 months of treatment. However, 
more studies are needed to evaluate the incidence of 
adverse events with cinacalcet therapy over time. Hypo-
calcemia was the main reason for withdrawing cinacalcet 
treatment, whereas gastrointestinal discomfort did not 
lead to the discontinuation of cinacalcet treatment in 
most cases. 
This study has some limitations. It was observational 
and retrospective. Therefore, relevant data might have 
been lost, and bias could have been introduced. This study 
analyzed surrogate parameters rather than hard clinical 
outcomes. However, cinacalcet treatment achieved a sus-
tained PTH reduction over time and seemed to maintain 
phosphorous values during 36 months in some patients. 
This study is the first to follow up non-dialysis patients 
on cinacalcet for up to 36 months; however, few patients 
were followed that long. Finally, the eGFR was calculated 
using two different equations, and PTH levels were mea-
sured using two different analyzers. Nevertheless, the re-
sults were not affected by those differences because the P 
significance value was far from 0.05 in most cases. Finally, 
urinary indices of calcium and phosphorus could not be 
assessed due to the lack of available data.
In conclusion, cinacalcet maintained reduced PTH 
levels for at least 36 months in non-dialysis patients. 
This effectiveness did not require a large increase in 
the cinacalcet dose. However, calcium and phosphorus 
levels should be monitored over time to prevent hypo-
calcemia and hyperphosphatemia. Hypocalcemia can 
be managed with the administration of vitamin D and its 
analogs. Cinacalcet treatment was associated with an in-
creased number of hyperphosphatemia cases; however, 
phosphorus levels remained unaffected or were reduced 
in some patients. Prospective studies are needed to cor-
roborate our observations and study the effects of cina-
calcet on cardiovascular morbidity and mortality in non-
dialysis patients. 
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